ASPRO C EFFERVESCENT TABLETS Milligram Tablets Effervescent

Nazione: Irlanda

Lingua: inglese

Fonte: HPRA (Health Products Regulatory Authority)

Compra

Scheda tecnica Scheda tecnica (SPC)
27-04-2024

Principio attivo:

ACETYLSALICYLIC ACID ASCORBIC ACID

Commercializzato da:

Bayer Limited

INN (Nome Internazionale):

ACETYLSALICYLIC ACID ASCORBIC ACID

Dosaggio:

Milligram

Forma farmaceutica:

Tablets Effervescent

Tipo di ricetta:

Product not subject to medical prescription

Stato dell'autorizzazione:

Withdrawn

Data dell'autorizzazione:

2009-08-26

Scheda tecnica

                                IRISH MEDICINES BOARD ACTS 1995 AND 2006
MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007
(S.I. NO.540 OF 2007)
PA1410/036/001
Case No: 2057285
The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to
BAYER LIMITED
THE ATRIUM, BLACKTHORN ROAD, DUBLIN 18
an authorisation, subject to the provisions of the said Regulations, in respect of the product
ASPRO C EFFERVESCENT TABLETS
The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as
may be specified in the said Regulations as listed on the reverse of this document.
This authorisation, unless previously revoked, shall continue in force from 29/07/2009.
Signed on behalf of the Irish Medicines Board this
________________
A person authorised in that behalf by the said Board.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 30/07/2009_
_CRN 2057285_
_page number: 1_
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
4 CLINICAL PARTICULARS
5 PHARMACOLOGICAL PROPERTIES
6 PHARMACEUTICAL PARTICULARS
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 30/07/2009_
_CRN 2057285_
_page number: 2_
                                
                                Leggi il documento completo